The medical technology continues to advance with the goal of improving the lives of patients. In this way, Samsung Electronics Switzerland is contributing to progress in this area with the development of its products.
Samsung has collaborated with Bottneuro AG, a Swiss medical and technology startup dedicated to improving the diagnosis and treatment of Alzheimer’s disease and to offer an innovative and improved solution to patients. Bottneuro AG has chosen the hardware of the Samsung Galaxy Tab S8+ Enterprise Edition to store and record therapy data in the Bottneuro solution.
Powerful therapy through innovative technology
Bottneuro AG technology identifies affected brain areas by the disease through 3D magnetic resonance imaging and positron emission tomography imaging data. Once identified, these regions can be targeted and electronically stimulated with Miamind® neurostimulator technology. The Galaxy Tab S8+ Enterprise Edition simplifies the management of the Bottneuro solution through a graphical interface.
Patients suffering from dementia often experience a reduction in your cognitive function in the first phases of the disease, causing the need to find an instrument that can easily operate and understand the goal of Bottneuro AG. With this intuitive interface and usability, the Galaxy Tab S8+ provided the optimal hardware for Bottneuro’s solution.
“We were looking for a simple and reliable solution for our application. We found it with the Galaxy Tab S8+ 5G Enterprise Edition and Samsung is giving us great support in development.”says Julius Klaas, CTO of Bottneuro AG.
Impeccable solutions in a single Galaxy Tablet
Galaxy Tab S8+ 5G Enterprise Edition offers different functionalities and features. It comes with a high-resolution Super AMOLED display that provides brilliant clarity for both patients and healthcare professionals and offers a long, reliable battery life.
The Miamind® neurostimulator is also powered by the Galaxy Tab S8+ 5G Enterprise Edition, and once treatment is complete, the Galaxy Tab S8+ automatically transmits diagnosis and treatment information from the Bottneuro solution to Bottneuro AG via a wireless connection. 5G data, allowing patients to be in the comfort of their homes. In addition, the Galaxy Tab S8+ 5G Enterprise Edition can be individually configured through Samsung Knox, keeping confidential information and medical records private and protected.
Cooperation for the future
Groundbreaking innovations like these couldn’t be possible without these collaborations, and Samsung is proud to have been supporting and working with Bottneuro AG since it was founded in 2021.
“We are pleased to offer Bottneuro AG a simple, safe and reliable solution with Samsung Knox and support its novel therapeutic approach”says Daniele Casella, Head of MX B2B Mobile at Samsung Electronics Switzerland.
The effectiveness of the new therapeutic treatment from Bottneuro AG will be tested in numerous clinical studies this year. Although the treatment is not yet commercially available, Bottneuro AG and Samsung remain optimistic about the progress that can be made in treating Alzheimer’s disease.
